During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Ruben Mesa, UT Health San Antonio, San Antonio, US. We asked, What is the long-term benefit of momelotinib treatment in relapsed/refractory myelofibrosis (MF)?
JAK inhibition has made a significant impact on patients with MF. Momelotinib is a JAK1/2 and ACVR1 inhibitor, which improves anemia and most importantly survival. Mesa also mentions the JAK inhibitor pipeline and which inhibitors will soon become available, offering more treatment options.